Alcoa News Release:
January 31, 2013
Alcoa Aluminum Wheels Recognized for Safety and Energy Efficiency in China
NEW YORK & BEIJING--(BUSINESS WIRE)--Alcoa (NYSE:AA) received a 2013 Accessory of the Year Award in the category of Best Safety and Energy Savings for the contributions of its forged aluminum wheels to China's bus manufacturing industry. The annual awards are organized by leading Chinese trade publicationsCNbuses.com and shangyongqiche.com and supported by the China Tourism News.
"We have been supplying Alcoa forged aluminum wheels to the Chinese bus market for nearly a decade,” said Tim Myers, President, Alcoa Wheel and Transportation Products. "This award acknowledges the important role our lightweight, durable wheels play in helping improve the performance and efficiency of commercial vehicles throughout China."
In selecting Alcoa Wheels for the award, the trade publications cited three factors: Alcoa's brand influence and reputation; the application of Alcoa's advanced process and technologies in the Chinese market; and Alcoa as an industry leader in helping lightweight the commercial vehicle industry.
Manufacturers, industry experts, media and the online public voted for winners in several categories including bus power, chassis, transmission, safety and energy savings, and smart technology.
Alcoa produces parts for various Chinese bus manufacturers, including Yutong, China's largest bus manufacturer, and Shenzhen Wuzhoulong Motors Co. Ltd. Alcoa's Super Single Wheels have contributed to better energy savings on Wuzhoulong's electric and hybrid buses.
Alcoa has had a presence in China since 2004, when it began selling wheels out of Shanghai. Since then, the business has grown to include an employee base in Guangzhou, Beijing, Jinan and Suzhou. Last December, Alcoa opened a production facility in Suzhou, China, marking an expansion that creates a full wheel manufacturing, distribution, sales and service network in China.
About Alcoa Wheels
Alcoa Wheel and Transportation Products, headquartered in Cleveland, Ohio, serves the commercial vehicle, automotive, and defense markets with products used in a range of applications including forged aluminum wheels, premium products such as Dura-Bright®, Dura-Flange®, LvL ONE® and M-Series™ medium truck wheels, as well as a variety of other aluminum components for these markets. AWTP is composed of three divisions: Commercial Vehicle Wheels, Forged Specialty Wheels and Transportation Products. It employs 1,500 people at 13 locations worldwide. More information can be found at www.alcoawheels.com.
About Alcoa
Alcoa is the world’s leading producer of primary and fabricated aluminum, as well as the world’s largest miner of bauxite and refiner of alumina. In addition to inventing the modern-day aluminum industry, Alcoa innovation has been behind major milestones in the aerospace, automotive, packaging, building and construction, commercial transportation, consumer electronics and industrial markets over the past 125 years. Among the solutions Alcoa markets are flat-rolled products, hard alloy extrusions, and forgings, as well as Alcoa® wheels, fastening systems, precision and investment castings, and building systems in addition to its expertise in other light metals such as titanium and nickel-based super alloys. Sustainability is an integral part of Alcoa’s operating practices and the product design and engineering it provides to customers. Alcoa has been a member of the Dow Jones Sustainability Index for 11 consecutive years and approximately 75 percent of all of the aluminum ever produced since 1888 is still in active use today. Alcoa employs approximately 61,000 people in 30 countries across the world. For more information, visitwww.alcoa.com and follow @Alcoa on Twitter at twitter.com/Alcoa.
Friday, February 1, 2013
Bank of America Announces Principal Closing of Sale of International Wealth Management Business Outside the United States to Julius Baer
Bank of America News Release:
Bank of America Announces Principal Closing of Sale of International Wealth Management Business Outside the United States to Julius Baer
CATEGORY:
Friday, February 1, 2013 7:00 am EST
Bank of America Corporation has announced that all pre-conditions necessary to allow principal closing of the sale of its International Wealth Management business based outside the United States have been met. As a result, ownership of Merrill Lynch Bank (Suisse) has today transferred to Julius Baer Group. Further transfers will occur in due course.
Bank of America
Bank of America is one of the world's largest financial institutions, serving individual consumers, small- and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 53 million consumer and small business relationships with approximately 5,500 retail banking offices and approximately 16,300 ATMs and award-winning online banking with 30 million active users. Bank of America is among the world's leading wealth management companies and is a global leader in corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 3 million small business owners through a suite of innovative, easy-to-use online products and services. The company serves clients through operations in more than 40 countries. Bank of America Corporation stock (NYSE: BAC) is a component of the Dow Jones Industrial Average and is listed on the New York Stock Exchange.
Bank of America is one of the world's largest financial institutions, serving individual consumers, small- and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 53 million consumer and small business relationships with approximately 5,500 retail banking offices and approximately 16,300 ATMs and award-winning online banking with 30 million active users. Bank of America is among the world's leading wealth management companies and is a global leader in corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 3 million small business owners through a suite of innovative, easy-to-use online products and services. The company serves clients through operations in more than 40 countries. Bank of America Corporation stock (NYSE: BAC) is a component of the Dow Jones Industrial Average and is listed on the New York Stock Exchange.
Visit the Bank of America newsroom for more Bank of America news.
Pfizer Wins RAPAMUNE® Patent Case in Delaware District Court
Pfizer News Release:
Pfizer Wins RAPAMUNE® Patent Case in Delaware District Court
Thursday, January 31, 2013 8:00 am EST
Dateline:
NEW YORK
Public Company Information:
NYSE:
PFE
US7170811035
"We are pleased with the Court’s decision, recognizing the validity of our patent."
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer’s patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed. The company brought a patent infringement action in April 2010 against the generic company Watson Laboratories, Inc—Florida (now known as Actavis) and three other Watson entities after Watson applied to the FDA to market a generic version of RAPAMUNE®. The Court’s decision prevents Watson from marketing its generic version of RAPAMUNE® in the U.S. before Pfizer’s patent expires, pending a possible appeal by Watson.
The patent at issue in the lawsuit is U.S. Patent No. 5,100,899, which including pediatric exclusivity, expires January 7, 2014. In response to the decision, Amy Schulman, Executive Vice President and General Counsel for Pfizer, said, “We are pleased with the Court’s decision, recognizing the validity of our patent."
In the United States, RAPAMUNE® is indicated for the prevention of organ transplant rejection in kidney transplant patients aged 13 years and older.
Important Safety Information
- There is an increased risk of developing infections or certain cancers, especially lymphoma and skin cancers.Rapamune has not been shown to be safe and effective in people who have had liver or lung transplants. Serious complications and death may happen in people who take Rapamune after a liver or lung transplant. You should not take Rapamune if you have had a liver or lung transplant without talking with your doctor.
- Do not take Rapamune if you know you are allergic to sirolimus or any of the other ingredients in Rapamune. Symptoms of an allergic reaction include swelling of your face, eyes, or mouth; trouble breathing or wheezing; throat tightness; chest pain or tightness; feeling dizzy or faint; and rash or peeling of your skin.
- Before taking Rapamune, tell your doctor if you have liver problems, skin cancer or it runs in your family, high cholesterol or triglycerides, are breastfeeding or plan to breastfeed, and are pregnant or plan to become pregnant. Women of childbearing potential should use effective birth control before therapy, during therapy, and for 12 weeks after Rapamune therapy has been stopped. Rapamune may interact with other medicines. Make sure that your doctor is aware of all prescription and over-the-counter drugs that you are taking, including vitamins, herbs, and nutritional supplements.
- Rapamune may cause swelling in your hands, feet, and in various tissues of your body. Call your doctor if you have trouble breathing.
- Rapamune may cause your wounds to heal slowly or not heal well resulting in redness, drainage, or opening of the wound.
- Rapamune may increase the levels of cholesterol and triglycerides (lipids or fat) in your blood. Your doctor should do blood tests to check your lipids during treatment with Rapamune. Your doctor may recommend treatment if your lipid levels become too high. Your lipid levels may remain high even if you follow your prescribed treatment plan.
- In patients taking Rapamune with cyclosporine, decreased kidney function has been observed. Your doctor will regularly check your kidney function.
- Rapamune may increase protein in your urine. Your doctor may monitor you for abnormal protein in your urine from time to time.
- Rapamune may increase your risk for viral infections. Certain viruses can live in your body and cause active infections when your immune system is weak. One of these viruses, BK virus, can affect how your kidney works and cause your transplanted kidney to fail. A certain virus can cause a rare serious brain infection called Progressive Multifocal Leukoencephalopathy causing death or severe disability.
- Rapamune may cause potentially life-threatening lung or breathing problems. Symptoms may include coughing, shortness of breath, or difficulty breathing.
- When Rapamune is taken with cyclosporine or tacrolimus, you may develop a blood clotting problem resulting in unexplained bleeding or bruising.
- Common side effects associated with Rapamune include high blood pressure, pain (including stomach and joint pain), diarrhea, headache, fever, urinary tract infection, low red blood cell count (anemia), nausea, and low platelet count (cells that help blood to clot). If you experience any side effects, contact your doctor.
Indications and Usage
RAPAMUNE® (sirolimus) is indicated for the prevention of organ rejection in kidney transplant patients aged 13 years or older. Blood levels of sirolimus should be checked in all patients taking Rapamune.
- In patients at low to moderate risk of acute rejection, it is recommended that Rapamune be used initially in combination with cyclosporine and corticosteroids; cyclosporine should be withdrawn approximately 3 months after transplantation. Cyclosporine withdrawal has not been studied in patients who have had severe acute rejection prior to cyclosporine withdrawal, those who require dialysis or have a high serum creatinine, Black patients, patients receiving a repeat kidney transplant, patients receiving other transplanted organs besides the kidney transplant, or patients with antibodies that may be directed against the kidney transplant.
- In patients at high risk of acute rejection (defined as Black patients and/or patients receiving a repeat kidney transplant who lost a previous kidney transplant from rejection and/or patients with high levels of antibodies that may be directed against the kidney transplant), it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation. The safety and efficacy of this combination in high-risk patients have not been studied beyond one year; therefore, after the first year, adjustments to the immunosuppressive regimen may be considered by your doctor.
In pediatric patients, the safety and efficacy of Rapamune have not been established in kidney transplant patients less than 13 years old, or in patients less than 18 years old who are considered at high risk of acute rejection.
- The safety and efficacy of Rapamune without cyclosporine in newly transplanted kidney patients have not been established.
- The safety and efficacy of changing from either cyclosporine or tacrolimus to Rapamune in maintenance kidney transplant patients have not been established.
Please see full Prescribing Information for Rapamune, including Boxed Warning and Medication Guide here.
Aetna Announces Leadership Changes in Line with Growth Strategy
Aetna News Release:
Aetna Announces Leadership Changes in Line with Growth Strategy
Joseph M. Zubretsky, Shawn M. Guertin, Karen S. Rohan Appointed to New Roles
Thursday, January 31, 2013 6:10 am EST
HARTFORD, Conn.--(BUSINESS WIRE)--Aetna (NYSE: AET) today announced changes to its executive leadership team as part of the company’s growth strategy and a continuing effort to align its businesses with the evolving needs of its customers. These new roles will report directly to Chairman, CEO and President Mark T. Bertolini.
Joseph M. Zubretsky, senior executive vice president and chief financial officer, will lead National Businesses, a new organization that includes Aetna’s National Accounts business, as well as Aetna’s emerging businesses, including Accountable Care Solutions, ActiveHealth Solutions, Medicity and iTriage. The organization Zubretsky will lead also includes Aetna’s national network contracting and care management areas; Aetna’s Specialty Products, including Behavioral Health, Pharmacy and Worker’s Compensation; and Enterprise Strategy and Corporate Development.
As part of the planned management transition, Zubretsky will be succeeded in his role as chief financial officer by Shawn M. Guertin, effective February 25, 2013. Guertin has most recently been Aetna’s head of Business Segment Finance, where he managed the finance organizations of all of Aetna’s businesses. Prior to joining Aetna in 2011, Guertin served for nearly five years as executive vice president, chief financial officer and treasurer of Coventry Health Care, Inc.
Karen S. Rohan, executive vice president, also will assume a newly created position leading Aetna’s Local and Regional Businesses. Rohan’s responsibilities will include leadership of the company’s Individual, Small Group and Middle Market businesses; its field organization, including regional alignment to customers; its local network strategy, regional sales and distribution infrastructure; and its Group businesses. Rohan will continue to lead Aetna’s integration efforts for its proposed acquisition of Coventry, which is expected to close in mid-2013.
“The management changes we are making ensure that we have Aetna’s strongest leaders focused on driving our growth strategy across our core and emerging businesses,” said Bertolini. “We have a unique opportunity to drive positive change in the health care marketplace by fundamentally changing the relationship between health plans, providers and patients to one focused on improving the quality of care as a way to reduce costs. Aligning Aetna’s Accountable Care Solutions, care management and national network organizations and our flagship National Accounts business strengthens our ability to move decisively toward that goal. Joe Zubretsky is the right leader to take this effort forward.
“After nearly two years of strong performance in senior financial roles at Aetna and with his in-depth knowledge of Coventry, Shawn Guertin is well prepared to step into the role of chief financial officer,” Bertolini said.
Bertolini added: “Our proposed acquisition of Coventry also represents a strong opportunity for Aetna to create long-term shareholder value. In order to successfully integrate Coventry, we need to take advantage of the best of both organizations. And in part that means getting decision making much closer to the customer, by empowering and strengthening our regional businesses. Combining these responsibilities under Karen Rohan will help drive that result.”
After 26 years in the industry and 20 years at Aetna, Frank McCauley will be retiring from Aetna later this year. McCauley has been a distinguished leader, beginning his career in the company’s Medicare business and moving on to successfully lead a wide variety of regional and national businesses to profitable growth. Most recently, he served as a member of Aetna’s executive committee and led Aetna’s Commercial businesses, including National Accounts, Individual, Small Group and Middle Markets.
“Frank and I have worked closely for eight years, and many Aetna successes can be attributed to his efforts,” Bertolini said. “He is respected by our leadership team and employees across the organization. Until his retirement, Frank will work with me on a number of initiatives, including preparing the company for health reform. We wish him the best in his future endeavors.”
About Aetna
Aetna is one of the nation's leading diversified health care benefits companies, serving approximately 37.3 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities, Medicaid health care management services and health information technology services. Our customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see www.aetna.com.
Aetna Announces Leadership Changes in Line with Growth Strategy
Joseph M. Zubretsky, Shawn M. Guertin, Karen S. Rohan Appointed to New Roles
Thursday, January 31, 2013 6:10 am EST
HARTFORD, Conn.--(BUSINESS WIRE)--Aetna (NYSE: AET) today announced changes to its executive leadership team as part of the company’s growth strategy and a continuing effort to align its businesses with the evolving needs of its customers. These new roles will report directly to Chairman, CEO and President Mark T. Bertolini.
Joseph M. Zubretsky, senior executive vice president and chief financial officer, will lead National Businesses, a new organization that includes Aetna’s National Accounts business, as well as Aetna’s emerging businesses, including Accountable Care Solutions, ActiveHealth Solutions, Medicity and iTriage. The organization Zubretsky will lead also includes Aetna’s national network contracting and care management areas; Aetna’s Specialty Products, including Behavioral Health, Pharmacy and Worker’s Compensation; and Enterprise Strategy and Corporate Development.
As part of the planned management transition, Zubretsky will be succeeded in his role as chief financial officer by Shawn M. Guertin, effective February 25, 2013. Guertin has most recently been Aetna’s head of Business Segment Finance, where he managed the finance organizations of all of Aetna’s businesses. Prior to joining Aetna in 2011, Guertin served for nearly five years as executive vice president, chief financial officer and treasurer of Coventry Health Care, Inc.
Karen S. Rohan, executive vice president, also will assume a newly created position leading Aetna’s Local and Regional Businesses. Rohan’s responsibilities will include leadership of the company’s Individual, Small Group and Middle Market businesses; its field organization, including regional alignment to customers; its local network strategy, regional sales and distribution infrastructure; and its Group businesses. Rohan will continue to lead Aetna’s integration efforts for its proposed acquisition of Coventry, which is expected to close in mid-2013.
“The management changes we are making ensure that we have Aetna’s strongest leaders focused on driving our growth strategy across our core and emerging businesses,” said Bertolini. “We have a unique opportunity to drive positive change in the health care marketplace by fundamentally changing the relationship between health plans, providers and patients to one focused on improving the quality of care as a way to reduce costs. Aligning Aetna’s Accountable Care Solutions, care management and national network organizations and our flagship National Accounts business strengthens our ability to move decisively toward that goal. Joe Zubretsky is the right leader to take this effort forward.
“After nearly two years of strong performance in senior financial roles at Aetna and with his in-depth knowledge of Coventry, Shawn Guertin is well prepared to step into the role of chief financial officer,” Bertolini said.
Bertolini added: “Our proposed acquisition of Coventry also represents a strong opportunity for Aetna to create long-term shareholder value. In order to successfully integrate Coventry, we need to take advantage of the best of both organizations. And in part that means getting decision making much closer to the customer, by empowering and strengthening our regional businesses. Combining these responsibilities under Karen Rohan will help drive that result.”
After 26 years in the industry and 20 years at Aetna, Frank McCauley will be retiring from Aetna later this year. McCauley has been a distinguished leader, beginning his career in the company’s Medicare business and moving on to successfully lead a wide variety of regional and national businesses to profitable growth. Most recently, he served as a member of Aetna’s executive committee and led Aetna’s Commercial businesses, including National Accounts, Individual, Small Group and Middle Markets.
“Frank and I have worked closely for eight years, and many Aetna successes can be attributed to his efforts,” Bertolini said. “He is respected by our leadership team and employees across the organization. Until his retirement, Frank will work with me on a number of initiatives, including preparing the company for health reform. We wish him the best in his future endeavors.”
About Aetna
Aetna is one of the nation's leading diversified health care benefits companies, serving approximately 37.3 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities, Medicaid health care management services and health information technology services. Our customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see www.aetna.com.
Marathon Petroleum Corporation Announces 2013 Annual Meeting of Stockholders
Marathon Petroleum Corporation has added a
news release to its Investor Relations website.
Title: Marathon Petroleum
Corporation Announces 2013 Annual Meeting of StockholdersDate(s): 31-Jan-2013 9:20 AM
For a complete listing of our news releases, please click here
FINDLAY, Ohio, Jan.
31, 2013 - Marathon Petroleum Corporation (NYSE: MPC) announced today that its
2013 annual meeting of stockholders will be held at the company's headquarters
in Findlay, Ohio, on April 24,
2013.
In addition, the company announced that Feb. 25, 2013, has been fixed as the record date for determination of the stockholders of the company entitled to notice of, and to vote at, the annual meeting.
In addition, the company announced that Feb. 25, 2013, has been fixed as the record date for determination of the stockholders of the company entitled to notice of, and to vote at, the annual meeting.
About Marathon
Petroleum Corporation
MPC is the nation's fifth-largest refiner with a crude oil refining capacity of approximately 1.2 million barrels per day in its six-refinery system. Marathon brand gasoline is sold through approximately 5,000 independently owned retail outlets across 17 states. In addition, Speedway LLC, an MPC subsidiary, owns and operates the nation's fourth-largest convenience store chain, with approximately 1,460 convenience stores in seven states. MPC also owns, leases or has ownership interests in approximately 8,300 miles of pipeline. Through subsidiaries, MPC owns the general partner of MPLX LP, a midstream master limited partnership. MPC's fully integrated system provides operational flexibility to move crude oil, feedstocks and petroleum-related products efficiently through the company's distribution network in the Midwest, Southeast and Gulf Coast regions. For additional information about the company, please visit our website at http://www.marathonpetroleum.com.
MPC is the nation's fifth-largest refiner with a crude oil refining capacity of approximately 1.2 million barrels per day in its six-refinery system. Marathon brand gasoline is sold through approximately 5,000 independently owned retail outlets across 17 states. In addition, Speedway LLC, an MPC subsidiary, owns and operates the nation's fourth-largest convenience store chain, with approximately 1,460 convenience stores in seven states. MPC also owns, leases or has ownership interests in approximately 8,300 miles of pipeline. Through subsidiaries, MPC owns the general partner of MPLX LP, a midstream master limited partnership. MPC's fully integrated system provides operational flexibility to move crude oil, feedstocks and petroleum-related products efficiently through the company's distribution network in the Midwest, Southeast and Gulf Coast regions. For additional information about the company, please visit our website at http://www.marathonpetroleum.com.
Subscribe to:
Posts (Atom)